Senior Clinical Trial Manager
As Senior Clinical Trial Manager I am responsible for overseeing a growing portfolio of studies and am responsible for the day to day management of the RIDD Trial, which is a clinical trial of an investigational medicinal product (CTIMP).
I have over 11 years’ experience of working in clinical research and prior to my current role have managed a number of Investigator-led clinical trials in oncology. These included both CTIMPs and non-CTIMPs, covering phase 1 to 3, protocol development to analysis and close-out. I have also worked as a Clinical Trial Monitor and in trial administration.
My background and training is as a scientist, with a D.Phil in Plant Genetics from the University of Oxford and a BSc (Hons) in Biochemistry & Genetics (Cert Ind) from the University of Leeds.
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.
Nanchahal J. et al, (2018), EBioMedicine, 33, 282 - 288
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS. et al, (2017), Lancet Oncol, 18, 1159 - 1171
Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.
Virdee PS. et al, (2017), JMIR Res Protoc, 6
SELECTIVE INTERNAL RADIOTHERAPY (SIRT) IN METASTATIC COLORECTAL CANCER PATIENTS WITH LIVER METASTASES: PRELIMINARY PRIMARY CARE RESOURCE USE AND UTILITY RESULTS FROM THE FOXFIRE RANDOMISED CONTROLLED TRIAL
Fusco R. et al, (2017), VALUE IN HEALTH, 20, A445 - A446
Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.
Eyre TA. et al, (2015), BMC Cancer, 15